Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 361 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Tumor markers Clear all

Conditions: Glioblastoma
Interventions: Temozolomide, partial brain irradiation, stereotactic biopsy of brain tumor, craniotomy and tumor resection; Drug · Radiation · Procedure
Lead sponsor: Tampa General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Breast Cancer
Interventions: Soy, Milk; Dietary Supplement
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Female only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Neurofibroma, Plexiform, Neurofibromatosis Type I
Interventions: tipifarnib, placebo; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 3 Years to 25 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 11
States / cities: Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 8 more

Conditions: Metastatic Breast Cancer, Tumor, Muscle Neoplasms, Chronic Pain
Interventions: Method(s)1 Attribution, Method(s)2 Attribution,; Drug
Lead sponsor: DR. DIANE CHISESI NFS. MD. PHD.; Other
Eligibility: 44 Years to 59 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Colorado Springs, Colorado

Conditions: Breast Cancer
Interventions: Narrative visualization, Standard self-regulation; Behavioral
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 55 Years to 79 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Lung Cancer, Lung Neoplasms, Cancer of Lung, Cancer of the Lung, Neoplasms, Lung, Neoplasms, Pulmonary, Pulmonary Cancer, Pulmonary Neoplasms, Carcinoma, Non-small-cell Lung, Adenocarcinoma, Squamous Cell Carcinoma
Interventions: Not listed
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Liver Neoplasms, Colonic Neoplasms, Metastatic Cancer to Liver
Interventions: Stereotactic Radiosurgery using the CyberKnife System.; Radiation
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Greenville, North Carolina

Conditions: Perioperative Inflammatory Response
Interventions: Simvastatin, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 80 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Hematopoietic Stem Cell Transplantation
Interventions: Melphalan; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Brain Neoplasms
Interventions: Propofol + Remifentanil, Sevoflurane + Remifentanil; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Cancer
Interventions: [18F]FluorThanatrace; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Cancer, Immune-related Adverse Event
Interventions: Medical chart review; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Radiation Injury, Breast Cancer
Interventions: Proton beam radiation therapy., X-ray based radiation therapy, Computed Tomography (CT) Scan, Pulmonary Function Test (PFT); Radiation · Procedure
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 2
States / cities: Gainesville, Florida • Jacksonville, Florida

Conditions: Women With Suspected or Confirmed Recurrent Breast Cancer
Interventions: Not listed
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 2
States / cities: Lancaster, Pennsylvania • Philadelphia, Pennsylvania

Conditions: Testicular Cancer
Interventions: Goal-Focused Emotion-Regulation Therapy (GET), Individual Supportive Listening; Behavioral
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years to 39 Years · Male only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Irvine, California

Conditions: Fasting, Breast Cancer, Survivorship, Breast Cancer Recurrent
Interventions: Fasting; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Prostate Cancer
Interventions: SpaceOAR Vue; Device
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: Male only
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Colorectal Polyps
Interventions: This is an observational study that has no interventions; Other
Lead sponsor: Viome; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Bothell, Washington

Conditions: Head and Neck Cancer, Lung Cancer, Lip Cancer, Lip Neoplasms, Head and Neck Cancers
Interventions: Tumor biopsy, Phlebotomy; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2027
U.S. locations: 1
States / cities: Stanford, California

Conditions: Survivorship, Cancer, Psychological Well-Being
Interventions: an empirically supported protocol, further refined with evidence-based strategies, Health education; Behavioral
Lead sponsor: George Washington University; Other
Eligibility: 18 Years to 39 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Bladder Cancer
Interventions: BCG vaccine, valrubicin, conventional surgery; Biological · Drug · Procedure
Lead sponsor: Anthra Pharmaceuticals; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2002
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Suicide, Attempted, Suicidal Ideation, Suicidal Intention, Suicide
Interventions: Clinical assessments and blood samples; follow-up for 12 mos, Clinical assessments and blood samples; no 12mo follow-up; Other
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 12 Years to 18 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Gastric Cancer
Interventions: small RNA-seq or array, ENLIGHT Assay; Diagnostic Test
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Breast Cancer
Interventions: GeneSearch™ Breast Lymph Node (BLN) Assay; Device
Lead sponsor: Janssen Diagnostics, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 6
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Clearwater, Florida + 3 more

Search by objective public record fields.

Preoperative Chemoradiation for Glioblastoma

Effect of Soy Supplementation on Cellular Markers in Normal and Cancerous Breast Tissue: A Randomized Placebo Controlled Study

R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas

Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor

Narrative Visualization for Breast Cancer Survivors' Physical Activity

Isolating and Testing Circulating Tumor DNA and Soluble Immune Markers During the Course of Treatment for Lung Cancer

Safety, Efficacy, and Dosing of Stereotactic Radiosurgery for Hepato-cellular Carc/Colo-rectal Liver Metastases

Assessing the Role of "Statin" Therapy and Perioperative Inflammatory Response in Patients Undergoing Major Orthopedic Surgery

A Pharmacokinetic Study of Melphalan in Children

Intravenous Anesthesia Versus Anesthesia With Volatile Agents in Elective Craniotomy for Tumors

PET Imaging of PARP Activity in Cancer

Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer Immunotherapy

Breast Cancer Lung Late Effects

Breast Cancer 2-PREVENT Translational Center of Excellence (TCE) - Metastatic Markers of Recurrent Tumor Phenotype for Breast Cancer

A Biobehavioral Intervention to Reduce Adverse Outcomes in Young Adult Testicular Cancer Survivors

Prolonged Nightly Fasting in Breast Cancer Survivors

Rectal Spacer for Prostate Cancer Radiation Image Guidance

Metatranscriptomic Markers of Colonic Neoplasia

Identification of Secreted Markers for Tumor Hypoxia in Patients With Head and Neck or Lung Cancers

mHealth for Young Adult Cancer Survivors

AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer

Biomarkers as Predictors of Suicidal Risk in Adolescents

Detection of Minimal Residual Disease Using Exosomal miRNA Distant Metastasis Markers

GeneSearch™ Breast Lymph Node (BLN) Assay Post Approval Study